We often hear that gene therapies are complex and require a lot of time and money to make. But what does that really mean? Tune in to hear experts in the field help answer this question by walking us through the manufacturing process.
Agenda
Introduction
12 – 12:05 p.m.
Laura Hameed, Executive Director, Columbus Children’s Foundation
How AAV Vectors Are Made
12:05 – 12:40 p.m.
David Dismuke, PhD, Chief Technical Officer, Forge Biologics
Michelle Berg, President, GMP Nucleic Acids, Aldevron
Dr. Dismuke and Ms. Berg will provide an integrated presentation highlighting the different methods for making AAV vectors, the importance of quality control and quality assurance at the different stages of drug development, as well as the current and future state of manufacturing capacity and timelines. They will also address the criticality of advanced planning for future success from the clinical and regulatory perspective and how costly (money and time) changes can be prevented.
Moderated Q&A
12:40 p.m. – 1:00 p.m.